Chemical reverses effects of ageing disease progeria in human skin cells
Study finds methylene blue can rescue mitochondrial defects in both progeria and normal skin cells.
Source: Gallo Images / Alamy Stock Photo
Progeria is a rare, fatal disorder of accelerated ageing in children resulting from a mutant protein produced in the cell nucleus. Growing evidence also suggests that mitochondrial defects play a role in the disease.
Researchers from the University of Maryland found that methylene blue – a chemical that has antioxidant effects in mitochondria – can rescue mitochondrial defects in both progeria and normal skin cells. Unexpectedly, the treatment also affects the nucleus, eliminating the nuclear “blebbing” characteristic of the disease and restoring nuclear functions.
“When we looked at the treated cells, it was hard to tell that they were progeria cells at all,” comments Kan Cao, senior co-author of the study, published in Aging Cell (online, 14 December 2015).
The team concludes that methylene blue is a promising drug for progeria and potentially normal ageing, and warrants further studies.
Citation: The Salvadore DOI: 10.1211/PJ.2015.20200302
Recommended from Pharmaceutical Press
Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.£38.00
Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.£38.00
This established textbook helps you differentiate between minor illnesses which can be safely managed in the pharmacy, and major diseases.£43.00
An practical, integrated approach to the pathophysiological and pharmacotherapeutic principles underlying the treatment of disease.£54.00
Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.£138.50